Media Articles Related to Rozerem (Ramelteon)
New guideline provides clinical recommendations for specific insomnia drugs
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.02.16]
DA new clinical practice guideline is the first from the American Academy of Sleep Medicine to provide comprehensive, evidence-based analyses of individual agents commonly used in the treatment of...
Insomnia increases asthma risk in adults
Source: Respiratory / Asthma News From Medical News Today [2017.02.02]
A new study suggests people who experience insomnia symptoms are at a higher risk of developing asthma in adulthood compared with insomnia-free adults.
Insomnia May Increase Adult Asthma Risk (CME/CE)
Source: MedPage Today Allergy & Immunology [2017.02.02]
(MedPage Today) -- New diagnoses seen three times as often in Norwegians with sleep trouble
Sleep Disorders: Insomnia, Sleep Apnea, and More
Source: MedicineNet Jet Lag Specialty [2016.08.22]
Title: Sleep Disorders: Insomnia, Sleep Apnea, and More
Created: 7/23/2010 2:39:00 PM
Last Editorial Review: 8/22/2016 12:00:00 AM
Sleep Better, Conquer Insomnia
Source: MedicineNet zolpidem Specialty [2016.06.24]
Title: Sleep Better, Conquer Insomnia
Created: 12/10/2008 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM
Published Studies Related to Rozerem (Ramelteon)
Ramelteon in the treatment of chronic insomnia: systematic review and
in the treatment of chronic insomnia... CONCLUSION: The efficacy and safety of ramelteon are promising for the chronic
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. [2011.10.01]
STUDY OBJECTIVES: To evaluate the next-morning residual effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects following bedtime dosing and a middle of the night awakening... CONCLUSIONS: Ramelteon (8 mg) and zopiclone (7.5 mg) significantly impaired driving performance, cognitive, memory, and psychomotor performance the morning following bedtime administration. In contrast to zopiclone, ramelteon produced no balance impairments. CLINICAL TRIAL IDENTIFIER: NCT00319215 (www.clinicaltrials.gov).
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. [2011.10]
OBJECTIVE: Few interventions have been successful to prevent or reverse the medical complications associated with antipsychotic agents in the schizophrenia population. In particular, no single agent can correct multiple metabolic abnormalities such as insulin resistance, hyperlipidemia, inflammation, obesity, and fat distribution. We now report a randomized placebo-controlled pilot study to examine the effects of ramelteon on obesity and metabolic disturbances among subjects with schizophrenia... CONCLUSIONS: Although ramelteon decreased cholesterol, treatment may have to be longer than 8 weeks and with a higher dose for maximal effect of ramelteon for body fat and lipid changes. Future studies are needed for patients with schizophrenia with a larger sample size to fully understand ramelteon's effects on abdominal adiposity and lipids.
Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. [2011.02]
This randomized, double-blind, placebo-controlled study assessed the efficacy and safety of ramelteon 4 and 8 mg in Japanese adults with chronic insomnia. A secondary objective was to evaluate efficacy and safety when doses were uptitrated from placebo, ramelteon 4 and 8 mg to 4, 8 and 16 mg, respectively...
Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. [2011.02]
OBJECTIVE: To assess patient-reported efficacy and safety of ramelteon in Japanese patients with chronic insomnia... CONCLUSIONS: In Japanese adults with chronic insomnia, ramelteon 8 mg significantly reduced patient-reported sleep latency, increased total sleep time and improved sleep quality after 1 week of treatment. Ramelteon was generally well tolerated with no rebound insomnia. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Clinical Trials Related to Rozerem (Ramelteon)
Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia. [Active, not recruiting]
To determine if administration of Rozerem in comparison to a placebo reduces or eliminates
gastroesophageal reflux disease(GERD) symptoms in individuals with both GERD and chronic
Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease [Terminated]
Patients with Parkinson's disease represent a significant proportion of VA elderly patients.
Sleep disturbances and caregiver burnout association with this condition represent a
significant problem. In this study, the investigators propose to perform an evaluation of a
fixed doe of ramelteon on sleep in VA outpatients diagnosed with Parkinson's disease.
The hypothesis to be examined is that ramelteon will improve the quality of sleep in
patients with Parkinson's disease while indirectly improving the quality of life for the
patients and caregivers. The investigators further hypothesize that these changes will
occur through restructuring and normalization of the sleep architecture.
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches [Terminated]
To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor
agonist used for insomnia, as a migraine prophylactic agent.
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder [Withdrawn]
Safety and Efficacy of Ramelteon in Healthy Subjects [Completed]
Reports of Suspected Rozerem (Ramelteon) Side Effects
Hepatic Function Abnormal (5),
Liver Disorder (5),
Cardio-Respiratory Arrest (5),
Depressed Level of Consciousness (5),
Pneumonia (3), more >>